HighTide Flags Trial Quality Issues After Completing Phase IIb MASH Study of HTD1801

Hightide Therapeutics Inc ( (HK:2511) ) just unveiled an update.

HighTide Therapeutics has completed its global multi-regional Phase IIb clinical trial of HTD1801 in patients with MASH and comorbid type 2 diabetes or pre-diabetes, but the study produced an unexpectedly high placebo response, raising concerns about trial execution and data integrity. A third-party review identified protocol and quality management issues, such as inappropriate changes in concomitant medications and patient compliance problems, prompting post hoc analyses that, after adjusting for these confounders, showed reduced placebo effects and a trend toward therapeutic benefit for HTD1801 along with safety consistent with prior studies; the company plans to reassess its MASH development strategy for HTD1801 and will consult the U.S. FDA before deciding on its future path.

The most recent analyst rating on (HK:2511) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Hightide Therapeutics Inc stock, see the HK:2511 Stock Forecast page.

More about Hightide Therapeutics Inc

HighTide Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for metabolic and liver diseases, including conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM). Its pipeline includes HTD1801, an investigational oral drug that has been evaluated in multiple Phase II and Phase III clinical trials targeting metabolic and hepatic disorders in patients with comorbid metabolic dysfunction.

Average Trading Volume: 517,008

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.39B

For detailed information about 2511 stock, go to TipRanks’ Stock Analysis page.